Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781679 | 0.83 | THRB (0.48) | THRBALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL18704269 | 0.81 | THRB (0.66) | THRBALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL20143283 | 0.79 | — | — | |
| SCHEMBL21300744 | 0.79 | — | — | |
| SCHEMBL9973625 | 0.78 | THRB (0.61) | THRBALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL13088010 | 0.77 | ALDH1A1 (0.44) | THRBALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL9973626 | 0.76 | THRB (0.59) | THRBALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL14207714 | 0.75 | — | — | |
| SCHEMBL10049421 | 0.75 | — | — | |
| SCHEMBL14938490 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-10875925-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200239580-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10442865-B2 | Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof | IMMUNOGEN, INC. (US) | 2019-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | THRB 3596/4885ALDH1A1 96/4885MAPT 4737/4885 |
| US-10442865-B2 | Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof | IL23R, CD22, IL2RA | THRB 2613/4885ALDH1A1 2090/4885MAPT 4283/4885 |
| US-10875925-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | THRB 2313/4885ALDH1A1 1167/4885MAPT 3609/4885 |
| US-20200239580-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | THRB 2313/4885ALDH1A1 1167/4885MAPT 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.